Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

Studied

This preclinical discovery program sought a once-weekly GLP-1 analogue with stronger albumin binding and stability against metabolic degradation.

Who / model

The abstract describes molecular optimization and pharmacokinetic testing in mini-pigs; it does not report a human efficacy trial or participant count.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Semaglutide was selected as the candidate. Compared with liraglutide, GLP-1-receptor affinity was threefold lower but albumin affinity was higher; mini-pig exposure supported once-weekly development.

Limits

This abstract provides preclinical pharmacology, not evidence of human effectiveness or safety; semaglutide was still in phase 3 testing at publication.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary